Katie L Thoren1, Jennifer M Colby2, Sarah B Shugarts3, Alan H B Wu2, Kara L Lynch2. 1. Department of Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY; thorenk@mskcc.org. 2. Department of Laboratory Medicine, University of California-San Francisco, San Francisco, CA; 3. Northern California Kaiser Permanente Regional Laboratory, Berkeley, CA.
Abstract
BACKGROUND: Liquid chromatography high-resolution mass spectrometry (LC-HRMS) with untargeted data collection is especially attractive for general unknown drug screening owing to its ability to identify unexpected compounds. LC-HRMS offers several advantages over traditional selected reaction monitoring (SRM) techniques and could be an ideal screening platform as long as its analytical performance is comparable to that of SRM-based methods. METHODS: We developed a broad-spectrum drug screen on a high-resolution mass spectrometer [tandem quadrupole time-of-flight (QqTOF)] that collected data in an untargeted manner and compared its performance to a nominal mass instrument [triple quadrupole linear ion trap (QqLIT)] that collected data in a targeted manner. Both methods used information-dependent acquisition of product ion spectra. We evaluated the lower limits of detection and matrix effects for each method and compared their ability to identify drugs in 100 routine clinical urine samples. Additional information (patient prescription history, drug screening results, etc.) was used to confirm discordant results. RESULTS: QqLIT was slightly more analytically sensitive than QqTOF; however, this difference did not significantly affect compound identification in patient samples. QqLIT identified 596 drugs in the urine samples, of which 531 (89%) were confirmed. QqTOF identified 515 drugs, of which 500 (97%) were confirmed. There were 562 instances of a confirmed drug (68 unique drugs) in the 100 urine samples; the methods were concordant in 469 of these instances. CONCLUSIONS: Overall, QqTOF performed similarly to QqLIT and could serve as an alternative method for general unknown screening.
BACKGROUND: Liquid chromatography high-resolution mass spectrometry (LC-HRMS) with untargeted data collection is especially attractive for general unknown drug screening owing to its ability to identify unexpected compounds. LC-HRMS offers several advantages over traditional selected reaction monitoring (SRM) techniques and could be an ideal screening platform as long as its analytical performance is comparable to that of SRM-based methods. METHODS: We developed a broad-spectrum drug screen on a high-resolution mass spectrometer [tandem quadrupole time-of-flight (QqTOF)] that collected data in an untargeted manner and compared its performance to a nominal mass instrument [triple quadrupole linear ion trap (QqLIT)] that collected data in a targeted manner. Both methods used information-dependent acquisition of product ion spectra. We evaluated the lower limits of detection and matrix effects for each method and compared their ability to identify drugs in 100 routine clinical urine samples. Additional information (patient prescription history, drug screening results, etc.) was used to confirm discordant results. RESULTS: QqLIT was slightly more analytically sensitive than QqTOF; however, this difference did not significantly affect compound identification in patient samples. QqLIT identified 596 drugs in the urine samples, of which 531 (89%) were confirmed. QqTOF identified 515 drugs, of which 500 (97%) were confirmed. There were 562 instances of a confirmed drug (68 unique drugs) in the 100 urine samples; the methods were concordant in 469 of these instances. CONCLUSIONS: Overall, QqTOF performed similarly to QqLIT and could serve as an alternative method for general unknown screening.
Authors: Tobias Kind; Hiroshi Tsugawa; Tomas Cajka; Yan Ma; Zijuan Lai; Sajjan S Mehta; Gert Wohlgemuth; Dinesh Kumar Barupal; Megan R Showalter; Masanori Arita; Oliver Fiehn Journal: Mass Spectrom Rev Date: 2017-04-24 Impact factor: 10.946
Authors: Elise D Riley; Felicia C Chow; S Andrew Josephson; Samantha E Dilworth; Kara L Lynch; Amanda N Wade; Carl Braun; Christopher P Hess Journal: J Stroke Cerebrovasc Dis Date: 2021-03-05 Impact factor: 2.136
Authors: Anthony J Tomassoni; Kathryn F Hawk; Karen Jubanyik; Daniel P Nogee; Thomas Durant; Kara L Lynch; Rushaben Patel; David Dinh; Andrew Ulrich; Gail D'Onofrio Journal: MMWR Morb Mortal Wkly Rep Date: 2017-02-03 Impact factor: 17.586
Authors: Elise D Riley; Eric Vittinghoff; Alan H B Wu; Phillip O Coffin; Priscilla Y Hsue; Dhruv S Kazi; Amanda Wade; Carl Braun; Kara L Lynch Journal: Drug Alcohol Depend Date: 2020-08-30 Impact factor: 4.492